Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology & Infectious Diseases 2018 M...
April 04 2018 - 8:00AM
Business Wire
Company secures four oral presentations,
including three that will highlight new data demonstrating activity
of rezafungin against Candida auris and azole-resistant
Aspergillus
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology
company developing novel anti-infectives including immunotherapies,
today announced that data from preclinical studies of its lead
antifungal rezafungin will be presented at the 28th European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
to be held in Madrid, Spain, April 21-24, 2018.
“At this year’s ECCMID meeting Cidara and our collaborators will
present a significant amount of new data highlighting the full
utility of rezafungin in areas of highest unmet need,” said Jeffrey
Stein, Ph.D., president and chief executive officer of Cidara.
“Rezafungin’s potent efficacy against Candida auris and
azole-resistant Aspergillus, as well as its substantial penetration
into the respiratory tract, strengthens the growing body of
evidence differentiating it in the treatment and prophylaxis of
deadly invasive fungal infections.”
ECCMID convenes leading experts from around the world to present
and discuss the latest research findings in infectious diseases,
infection control and clinical microbiology. A total of five
presentations at the 2018 ECCMID Congress, comprising four oral
presentations and one poster, will report data evaluating Cidara’s
lead antifungal rezafungin, the only once-weekly product candidate
in development for the treatment and prevention of life-threatening
invasive fungal infections.
Details of the five ECCMID presentations are as follows:
Oral Presentations
Title: Multicentre determination of CD101 (rezafungin)
susceptibility of Candida species by the EUCAST
methodAuthor: Arendrup, et. al.Date and time:
Tuesday, April 24, 9:22-9:32 a.m. CETLocation: Hall K, IFEMA
– Feria de MadridPresentation number: #O0938Oral
Session: News on Antifungal Therapy
Title: Rezafungin (CD101) demonstrates potent in vitro
activity against Aspergillus, including azole-resistant A.
fumigatus isolates and cryptic speciesAuthor: Wiederhold,
et. al.Date and time: Tuesday, April 24, 9:34-9:44 a.m.
CETLocation: Hall K, IFEMA – Feria de MadridPresentation
number: #O0939Oral Session: News on Antifungal
Therapy
Title: EUCAST susceptibility testing of rezafungin
(CD101): activity against Candida aurisAuthor: Arendrup, et.
al.Date and time: Tuesday, April 24, 10:10-10:20 a.m.
CETLocation: Hall K, IFEMA – Feria de MadridPoster
number: #O0942Oral Session: News on Antifungal
Therapy
Title: Pharmacodynamic (PD) evaluation of rezafungin
against Candida auris in the persistently neutropenic murine model
of disseminated candidiasisAuthor: Lepak (Andes), et.
al.Date and time: Tuesday, April 24, 10:34-10:44 a.m.
CETLocation: Hall K, IFEMA – Feria de MadridPoster
number: #O0944Oral Session: News on Antifungal
Therapy
Poster Presentation
Title: High and sustained lung epithelial lining fluid
(ELF)-to-plasma exposure ratio from a single dose of rezafungin
(CD101): efficacy comparison to posaconazole and micafungin in a
mouse pulmonary aspergillosis infection modelAuthor: Ong,
et. al.Date and time: Saturday, April 21, 3:30-4:30 p.m.
CETLocation: Paper Poster Arena, IFEMA – Feria de
MadridPoster number: #P0173Poster Session:
Aspergillus in the Laboratory
Copies of these presentations will be available on the Cidara
website following the meeting: www.cidara.com
About Invasive Fungal Infections
Invasive fungal infections (IFIs) represent a serious threat to
millions of patients worldwide, resulting in more than 1.5 million
deaths annually and mortality rates ranging from 15 to 65 percent.
These infections are especially relevant for patients whose immune
systems have been compromised, such as patients undergoing bone
marrow transplantation (BMT) or chemotherapy. Of the most
significant IFIs, approximately 90 percent of related deaths are
primarily caused by Candida, Aspergillus, and Pneumocystis. Candida
auris (also called C. auris) has become a growing public health
concern and can cause bloodstream infections and even death,
particularly in hospital and nursing home patients with serious
medical problems. According to the Centers for Disease Control and
Prevention, more than one in three patients with invasive C. auris
infection die.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
rezafungin acetate, formerly known as CD101 IV, through clinical
trials. Rezafungin has improved pharmacokinetics compared to
existing echinocandins and the potential for expanded utility
across patient settings. It is the only once-weekly product
candidate in development for the treatment and prevention of
life-threatening invasive fungal infections. The company’s Phase 2
STRIVE clinical trial of rezafungin met its primary safety and
efficacy objectives, and Cidara plans to initiate Phase 3 pivotal
trials in the treatment of candidemia and invasive candidiasis and
the prophylaxis of invasive fungal infections in 2018. Cidara also
is leveraging its novel Cloudbreak™ platform to develop
antibody-drug conjugates for the treatment of multi-drug resistant
Gram-negative bacterial infections. Cloudbreak is the first
immunotherapy discovery platform designed specifically to create
compounds that directly kill pathogens and also direct a patient’s
immune cells to attack and eliminate bacterial, fungal or viral
pathogens. Cidara is headquartered in San Diego, California. For
more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, the potential for
rezafungin to successfully treat or prevent invasive fungal
infections and represent an improvement over current approaches,
and Cidara’s ability to successfully develop rezafungin. Risks that
contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in the United
States and foreign countries; changes in Cidara’s plans to develop
and commercialize its product candidates; Cidara’s ability to
obtain additional financing; Cidara’s ability to obtain and
maintain intellectual property protection for its product
candidates; and the loss of key scientific or management personnel.
These and other risks and uncertainties are described more fully in
Cidara’s Form 10-Q most recently filed with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Cidara undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180404005145/en/
Cidara Therapeutics, Inc.INVESTOR CONTACT:Westwicke
Partners, LLCRobert H. Uhl, 858-356-5932Managing
Directorrobert.uhl@westwicke.comorMEDIA CONTACT:Sam Brown
Inc.Christy Curran, 615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024